Implementation of a Personalized Risk Model for Lymph Node Metastasis in Endometrial Carcinoma: Healthcare Providers' Perspectives on Use, Barriers, and Facilitators
Cancer Medicine · 2025
DOI: 10.1002/cam4.71103 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Marike S Lombaers und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, the Netherlands. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Health Personnel, Attitude of Health Personnel. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KWF Kankerbestrijding.
Abstract (Originalsprache)
Background
The ENDORISK model estimates the risk of lymph node metastases (LNM) in endometrial carcinoma (EC) patients using preoperative clinical variables and biomarkers. This qualitative study investigated healthcare providers' (HCP) perspectives on the use of the model and barriers and facilitators for clinical implementation.
Methods
Eight focus group interviews were performed among HCPs. A semi‐structured interview guide was used based on the Grol and Wensing implementation model.
Results
Focus groups included gynecologists, residents of gynecology, pathologists, radiation oncologists, and a nurse specialist ( n = 41). ENDORISK was deemed supportive for counseling of patients and shared decision‐making for optimal surgical and adjuvant treatment. Barriers for implementation were difficulty in explaining the model and risk percentages to patients, differences in preoperative diagnostic tools used per hospital, and use of the model with the sentinel node procedure. Facilitators were a clear guideline for using the model with a predefined risk cutoff and making the model easily understandable for patients. A 10% risk cutoff was considered clinically relevant for lymph node assessment.
Conclusion
HCP found ENDORISK use in clinical practice supportive for patient counseling. Future implementation should focus on a user‐friendly interface, a cohesive guideline, and training to aid efficient use and counseling of patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, the Netherlands.
- Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
- Department of Obstetrics and Gynecology, Catharina Hospital, Eindhoven, the Netherlands.
- Department of Pathology, Eurofins PAMM, Eindhoven, the Netherlands.
- Netherlands Comprehensive Cancer Organization, Eindhoven, the Netherlands.
- Scientific Center for Quality of Health care (IQ Health), Radboud University Medical Center, Nijmegen, the Netherlands.
ORCID-Profile: Marike S Lombaers, Casper Reijnen, Johanna M A Pijnenborg
Förderung
- KWF Kankerbestrijding
Zitieren
APA
Lombaers, M. S., Vrede, S. W., Reijnen, C., Boll, D., Visser, N. C. M., Pijnenborg, J. M. A., Ezendam, N. P. M., & Hermens, R. P. M. G. (2025). Implementation of a Personalized Risk Model for Lymph Node Metastasis in Endometrial Carcinoma: Healthcare Providers' Perspectives on Use, Barriers, and Facilitators. Cancer Medicine. https://doi.org/10.1002/cam4.71103
Vancouver
Lombaers MS, Vrede SW, Reijnen C, Boll D, Visser NCM, Pijnenborg JMA, et al. Implementation of a Personalized Risk Model for Lymph Node Metastasis in Endometrial Carcinoma: Healthcare Providers' Perspectives on Use, Barriers, and Facilitators. Cancer Medicine. 2025. doi:10.1002/cam4.71103
BibTeX
@article{Lombaers2025,
author = {Lombaers, Marike S and Vrede, Stephanie W and Reijnen, Casper and Boll, Dorry and Visser, Nicole C M and Pijnenborg, Johanna M A and Ezendam, Nicole P M and Hermens, Rosella P M G},
title = {Implementation of a Personalized Risk Model for Lymph Node Metastasis in Endometrial Carcinoma: Healthcare Providers' Perspectives on Use, Barriers, and Facilitators},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71103}
}
EUVIMED